Mumps Vaccines: Current Challenges and Future Prospects

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2020 Sep 25

PMID 32973721

Citations 14

Authors

Iman Almansour

Affiliations

Soon will be listed here.

Abstract

Five decades have passed since the first mumps vaccine was licensed. Over this period, a resurgence of mumps infections has been recorded worldwide. Although global mumps infections have been controlled through vaccination, outbreaks are still on the rise, including in populations with high vaccination coverage. Several epidemiological studies suggest that this infectious virus continues to be a worldwide public health threat. The development and deployment of an improved, prophylactic mumps vaccine that provides long-lasting protection is indeed a priority. The purpose of this review is to provide an immuno-biological perspective on mumps vaccines. Here, we review the virology of mumps, licensed mumps vaccines, and the typical immune responses elicited following mumps vaccination. Furthermore, we discuss the limitations and challenges of the currently licensed mumps vaccines and provide strategies for the development of an improved mumps vaccine.

Citing Articles

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K Vaccines (Basel). 2025; 12(12.

PMID: 39772061 PMC: 11728456. DOI: 10.3390/vaccines12121401.

Exploration of microRNAs as transcriptional regulator in mumps virus infection through computational studies.

Hassan M, Shahzadi S, Iqbal M, Yaseeen Z, Kloczkowski A Sci Rep. 2024; 14(1):18850.

PMID: 39143101 PMC: 11324793. DOI: 10.1038/s41598-024-67717-z.

Epidemiologic and clinical updates on viral infections in Saudi Arabia.

Alshiban N, Aleyiydi M, Nassar M, Alhumaid N, Almangour T, Tawfik Y Saudi Pharm J. 2024; 32(7):102126.

PMID: 38966679 PMC: 11223122. DOI: 10.1016/j.jsps.2024.102126.

Three SARS-CoV-2 spike protein variants delivered intranasally by measles and mumps vaccines are broadly protective.

Zhang Y, Chamblee M, Xu J, Qu P, Shamseldin M, Yoo S Nat Commun. 2024; 15(1):5589.

PMID: 38961063 PMC: 11222507. DOI: 10.1038/s41467-024-49443-2.

Immunogenicity and Cross-Protection Efficacy of a Genotype F-Derived Attenuated Virus Vaccine Candidate against Mumps Virus in Mice.

Kim S, Won H, Hwang Y, Kim S, Lee J, Kim D Vaccines (Basel). 2024; 12(6).

PMID: 38932324 PMC: 11209446. DOI: 10.3390/vaccines12060595.

References

Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron C . Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006. Vaccine. 2008; 26(29-30):3601-7. DOI: 10.1016/j.vaccine.2008.04.075. View

Kingston R, Baase W, Gay L . Characterization of nucleocapsid binding by the measles virus and mumps virus phosphoproteins. J Virol. 2004; 78(16):8630-40. PMC: 479056. DOI: 10.1128/JVI.78.16.8630-8640.2004. View

Xu P, Li Z, Sun D, Lin Y, Wu J, Rota P . Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus. Virology. 2011; 417(1):126-36. PMC: 3959920. DOI: 10.1016/j.virol.2011.05.003. View

Kubota T, Yokosawa N, Yokota S, Fujii N, Tashiro M, Kato A . Mumps virus V protein antagonizes interferon without the complete degradation of STAT1. J Virol. 2005; 79(7):4451-9. PMC: 1061565. DOI: 10.1128/JVI.79.7.4451-4459.2005. View

Matsubara K, Iwata S, Nakayama T . Antibodies against mumps virus component proteins. J Infect Chemother. 2012; 18(4):466-71. DOI: 10.1007/s10156-011-0358-3. View

Germann D, Strohle A, Eggenberger K, Steiner C, Matter L . An outbreak of mumps in a population partially vaccinated with the Rubini strain. Scand J Infect Dis. 1996; 28(3):235-8. DOI: 10.3109/00365549609027163. View

Lohia N, Baranwal M . Conserved peptides containing overlapping CD4+ and CD8+ T-cell epitopes in the H1N1 influenza virus: an immunoinformatics approach. Viral Immunol. 2014; 27(5):225-34. DOI: 10.1089/vim.2013.0135. View

Ulane C, Rodriguez J, Parisien J, Horvath C . STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol. 2003; 77(11):6385-93. PMC: 155014. DOI: 10.1128/jvi.77.11.6385-6393.2003. View

Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J . Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001; 184(7):817-26. DOI: 10.1086/323346. View

10.

Nalin D . Mumps vaccine complications: which strain?. Lancet. 1989; 2(8676):1396. DOI: 10.1016/s0140-6736(89)92004-7. View

11.

BUYNAK E, HILLEMAN M . Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med. 1966; 123(3):768-75. DOI: 10.3181/00379727-123-31599. View

12.

Takeuchi K, Tanabayashi K, Hishiyama M, Yamada A . The mumps virus SH protein is a membrane protein and not essential for virus growth. Virology. 1996; 225(1):156-62. DOI: 10.1006/viro.1996.0583. View

13.

Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A . Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993; 341(8851):979-82. DOI: 10.1016/0140-6736(93)91069-x. View

14.

Goncalves G, de Araujo A, Monteiro Cardoso M . Outbreak of mumps associated with poor vaccine efficacy - Oporto Portugal 1996. Euro Surveill. 2003; 3(12):119-121. DOI: 10.2807/esm.03.12.00101-en. View

15.

Xu P, Chen Z, Phan S, Pickar A, He B . Immunogenicity of novel mumps vaccine candidates generated by genetic modification. J Virol. 2013; 88(5):2600-10. PMC: 3958107. DOI: 10.1128/JVI.02778-13. View

16.

Wilson R, Fuentes S, Wang P, Taddeo E, Klatt A, Henderson A . Function of small hydrophobic proteins of paramyxovirus. J Virol. 2006; 80(4):1700-9. PMC: 1367141. DOI: 10.1128/JVI.80.4.1700-1709.2006. View

17.

Cardemil C, Dahl R, James L, Wannemuehler K, Gary H, Shah M . Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med. 2017; 377(10):947-956. PMC: 6546095. DOI: 10.1056/NEJMoa1703309. View

18.

Schaffzin J, Pollock L, Schulte C, Henry K, Dayan G, Blog D . Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics. 2007; 120(4):e862-8. DOI: 10.1542/peds.2006-3451. View

19.

BUYNAK E, Whitman Jr J, ROEHM R, Morton D, Lampson G, HILLEMAN M . Comparison of neutralization and hemagglutination-inhibition techniques for measuring mumps antibody. Proc Soc Exp Biol Med. 1967; 125(4):1068-71. DOI: 10.3181/00379727-125-32278. View

20.

Ong G, Goh K, Ma S, Chew S . Comparative efficacy of Rubini, Jeryl-Lynn and Urabe mumps vaccine in an Asian population. J Infect. 2005; 51(4):294-8. DOI: 10.1016/j.jinf.2004.10.001. View